ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 1522 • ACR Convergence 2024

    Impact of Thrombocytopenia on In-hospital Mortality and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus: An Analysis of the National Inpatient Sample Database 2020

    Soziema Salia1, Ufuoma Mamoh2, Gilava Hedayati2, Joseph Atarere3, Raymond Wadie4, Boniface Mensah3, Joan Morny5 and Indira Acharya6, 1MedStar Union Memorial Hospital, Towson, MD, 2Medstar Union Memorial Hospital, Baltimore, MD, 3Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, MD, 4Department of Internal Medicine, Cayuga Medical Center, Ithaca, NY, 5Piedmont Athens Regional Medical Center, Athens, GA, 6Medstar Internal Medicine Residency Program, Baltimore, MD

    Background/Purpose: Thrombocytopenia is associated with Systemic Lupus Erythematosus (SLE) and occurs at various stages of the disease. It is reported in an estimated 10% to 40% of…
  • Abstract Number: 1542 • ACR Convergence 2024

    Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus

    Arezou Khosroshahi1, Sarah Welsh2, Liangwei Wang2, David Larson2 and Nisha Jain2, 1Emory University, Atlanta, GA, 2Amgen, Inc., Rockville, MD

    Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…
  • Abstract Number: 1651 • ACR Convergence 2024

    Unlocking the Secrets of Breg Dysfunction in Lupus: Glycosylation Patterns as Therapeutic Targets

    Pauline Kerleroux-Trébaol1, Marie Morel1, Sandrine Jousse-Joulin2, Divi Cornec3, Pierre Pochard1 and Anne Bordron1, 1Université de Bretagne Occidentale, brest, France, 2cavale blanche hospital, brest, France, 3Service de Rhumatologie, CHU de Brest, Brest, France

    Background/Purpose: The immune system is a complex network of cells preventing the invasion of the organism from external particles. The break in the homeostasis will…
  • Abstract Number: 1753 • ACR Convergence 2024

    A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases

    Georg Schett1, Emily Littlejohn2, Neil Kramer3, Amit Saxena4, Philip Mease5, Margrit Wiesendanger6, Fabian Müller7, Ran Reshef8, Paolo Caimi9, Mohamad Cherry10, Jingmei Hsu4, Krish Patel11, Jacques Azzi6, Susana Falcon12, Thomas Ly13, Ken Ogasawara12, Sharmila Das12, Jerill Thorpe14, Michael Maldonado12, Giuseppina Stifano12, Ashley Koegel12 and Anca Askanase15, 1Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 2Cleveland Clinic, Cleveland, OH, 3Atlantic Medical Group, Atlantic Health System, Morristown, NJ, 4NYU Grossman School of Medicine, New York, NY, 5Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 6Icahn School of Medicine at Mount Sinai, New York, NY, 7Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, 8Columbia University Irving Medical Center, New York, NY, 9Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, 10Atlantic Health System, Morristown, NJ, 11Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA, 12Bristol Myers Squibb, Princeton, NJ, 13Bristol Myers Squibb, San Diego, CA, 14Bristol Myers Squibb, Seattle, WA, 15Columbia University Medical Center, New York, NY

    Background/Purpose: CD19 is an appealing therapeutic target due to its ubiquitous expression on B cells and plasmablasts, which play a key role in the pathogenesis…
  • Abstract Number: 1793 • ACR Convergence 2024

    SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages

    Jessica Shannon and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…
  • Abstract Number: 1839 • ACR Convergence 2024

    PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways

    Xuan Fang, Xiangpei Li and Xiaomei Li, The First Affiliated Hospital of University of Science and Technology of China., He Fei, China (People's Republic)

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is distinguished by immune system dysfunction, leading to heightened activation of T and B cells. This increased activity leads to…
  • Abstract Number: 2049 • ACR Convergence 2024

    Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study

    Dongze Wu1 and Yingzhao jin2, 1Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China (People's Republic), 2Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: There are conflicting findings on the relationship between glucose-lowering drugs and risk of development of immune mediated inflammatory diseases (IMIDs). The study aimed to…
  • Abstract Number: 2377 • ACR Convergence 2024

    Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY

    Anitha Ramu1, Justina Shafik2, Maedeh Ashrafi3, Juliann Allen2, Kiera Brennan1 and Noa Schwartz4, 1Montefiore Medical Center, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Jacobi Medical Center, Bronx, NY, 4Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Studies have demonstrated that socioeconomic status (SES) significantly influences outcomes of patients with SLE.1 Traditionally, tools such as income, education, occupation, and housing have…
  • Abstract Number: 2396 • ACR Convergence 2024

    PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE

    Anna Korogodina1, Erin Sundel1, Yaroslav Markov2, Vasileios Kyttaris3, Julianne O'Connell1 and Suzanne Krishfield1, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Yale School of Medicine, New Haven, 3BIDMC, Boston, MA

    Background/Purpose: SLE-related outcomes are traditionally assessed by clinician-derived measures. However, these assessments often do not fully capture how patients experience their disease. We assessed the alignment…
  • Abstract Number: 2414 • ACR Convergence 2024

    A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry

    Alma Aveytia Camacho1, Rakesh Gullapelli2, Vineetha Philip3, Soudabeh Daliri1, Ruba Memon4, Helene DiGregorio2, Lily Romero Karam2, Kanika Monga3, Eleonora Avenatti2, Khurram Nasir2 and Myriam Guevara1, 1Houston Methodist, Houston, TX, 2Houston Methodist Hospital, Houston, TX, 3Houston Methodist Hospital, Sugar Land, TX, 4Houston Methodist, Missouri City, TX

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased prevalence of cardiovascular risk factors (RFs), which predispose to higher risk of premature atherosclerotic cardiovascular disease…
  • Abstract Number: 2430 • ACR Convergence 2024

    Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial

    Alex S. Powlesland1, Ioana Cutcutache1, Andrew Skelton1, Anthony Shock1, Matthew Page1, Eris Bame2, Janine Gaiha-Rohrbach2, George Stojan3, Ania Skowera1, Christian Stach4 and Thomas Dörner5, 1UCB Pharma, Slough, United Kingdom, 2Biogen Inc., Cambridge, MA, 3UCB Pharma, Atlanta, GA, 4UCB Pharma, Monheim am Rheim, Germany, 5Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany

    Background/Purpose: CD40-CD40L interactions play a pivotal role in systemic lupus erythematosus (SLE) pathogenesis by orchestrating a range of immune and inflammatory responses involving B cells,…
  • Abstract Number: 2576 • ACR Convergence 2024

    Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis

    April Jorge1, Aakash Patel1, Baijun Zhou2, Yuqing Zhang3 and Hyon K. Choi4, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
  • Abstract Number: 2658 • ACR Convergence 2024

    Hypovitaminosis D in Lupus Nephitis

    Alicia Yupe1, Emma Puron Gonzalez2, Esteban Salatino3, Jessica Santana4, Montserrat Ochoa4, Rosa Elena Cervantes-Ramirez5, Eli Marisol Saldaña6, gabriel Calderon7, Brissia Ceniceros8, Ulices de la Cruz9, Monica Meza10 and Sergio Cerpa Cruz6, 1Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala., Guatemala, Guatemala, 2UDEM/ITESM, San Pedro Garza Garcia, Mexico, 3Faculty of Medical Sciences, Universidad de San Carlos de Guatemala., Guatemala, GU, 4Hospital Civil "Fray Antonio Alcalde", Guadalajara, Mexico, 5Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico, Distrito Federal, Mexico, 6Hospital Civil de Guadalajara, Guadalajara, Mexico, 7Hospital Civil de Guadalajara, Monterrey, Mexico, 8Hospital Civil de Guadalajara, Torreón, Coahuila de Zaragoza, Mexico, 9Hospital Civil "Fray Antonio Alcalde", Guadalajara, 10Centro Universitario de Ciencias de la SAlud, Guadalajara

    Background/Purpose: The prevalence of vitamin D deficiency is higher in patients with systemic lupus erythematosus (SLE) compared to the healthy population, and recent studies have…
  • Abstract Number: 0008 • ACR Convergence 2024

    Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease

    Ashley Mahne1, Ryan Rodriguez2, Jessica Wang1, Daniel Anaya1, Joseph K. Cheng1, Brandon Kwong1, Jesus Banuelos3, Peter Starokadomskyy3, Soo Park3, Candice Gibson4, Shouvonik Sengupta1, Simone Sandoval1, Jazmin Bravo3, Jeanne Flandez1, Shairaz Shah1, Amanda Goodsell1, Nicole Khoshnoodi1, Jennifer Zeng1, Santiago Foos-Russ1, Mario Lorente1, Jennifer Adrian1, Timothy Klasson1, Yong Zhang5, Jessica Seitzer6, Birgit Schultes5 and Tom Van Blarcom3, 1Kyverna Therapeutics, Inc., Emeryville, CA, 2Kyverna Therapeutics, Inc., Emerville, CA, 3Kyverna Therapeutics, Inc., Emeryville, 4Kyverna Therapeutics, Inc., Emerybille, 5Intellia Therapeutics, Inc., Cambridge, MA, 6Intellia Therapeutics, Inc., Cambridge

    Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
  • Abstract Number: 0106 • ACR Convergence 2024

    IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS

    Christina Donath1, Sara Kahlown1, Ryan Soares2, Kamal Gautam2, Mariam Saleh3, Banki Katalin4 and Andras Perl5, 1SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, 2SUNY Upstate University Hospital, Department of Medicine, Internal Medicine Residency Program, Syracuse, NY, 3SUNY Upstate University Hospital, Syracuse, NY, 4SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, 5SUNY, Syracuse, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology